Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-κB ligand and osteoprotegerin in osteoblasts

被引:78
|
作者
Takami, M
Takahashi, N
Udagawa, N
Miyaura, C
Suda, K
Woo, JT
Martin, TJ
Nagai, K
Suda, T
机构
[1] Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, Tokyo 1428555, Japan
[2] Tokyo Inst Technol, Dept Bioengn, Yokohama, Kanagawa 2268501, Japan
[3] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Biochem, Tokyo 1920392, Japan
[4] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia
关键词
D O I
10.1210/en.141.12.4711
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) produced by osteoblasts/stromal cells are involved as positive and negative regulators in osteoclast formation. Three independent signals have been proposed to induce RANKL expression in osteoblasts/stromal cells: vitamin D receptor-, cAMP-, and gp130-mediated signals. We previously reported that intracellular calcium-elevating compounds such as ionomycin, cyclopiazonic acid, and thapsigargin induced osteoclast formation in cocultures of mouse bone marrow cells and primary osteoblasts. Increases in calcium concentration in culture medium also induced osteoclast formation in cocultures. Treatment of primary osteoblasts with these compounds or with high calcium medium stimulated the expression of both RANKL and OPG messenger RNAs (mRNAs). 1,2-Bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid)-tetra(acetoxymethyl)ester, an intracellular calcium chelator, suppressed both ionamycin-induced osteoclast formation in cocultures and expression of RANKL and OPG mRNAs in primary osteoblasts. Phorbol 12-myristate 13-acetate (PMA), an activator of protein kinase C, also stimulated osteoclast formation in these cocultures and the expression of RANKL and OPG mRNAs in primary osteoblasts. Protein kinase C inhibitors such as calphostin and staurosporin suppressed ionomycin- and PMA-induced osteoclast formation in cocultures and expression of RANKL and OPG mRNAs in primary osteoblasts. Ionomycin stimulated RANKL mRNA expression in ST2 and MC3T3-G2/PA6 cells, but not in MC3T3-E1 or NIH-3T3 cells. These effects were closely correlated with osteoclast formation in response to ionomycin in cocultures with these stromal cell lines. OPG strongly inhibited osteoclast formation induced by calcium-elevating compounds and PMA in cocultures, suggesting that RANKL expression in osteoblasts is a rate-limiting step for osteoclast induction. Forskolin, an activator of cAMP signals, also stimulated osteoclast formation in cocultures. Forskolin enhanced RANKL mRNA expression but suppressed OPG mRNA expression in primary osteoblasts. These results suggest that the calcium/protein kinase C signal in osteoblasts/stromal cells is the fourth signal for inducing RANKL mRNA expression, which, in turn, stimulates osteoclast formation.
引用
收藏
页码:4711 / 4719
页数:9
相关论文
共 50 条
  • [1] Effect of gallium nitrate on the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand in osteoblasts in vivo and in vitro
    Li, Jingwu
    Wang, Guang-Bin
    Peng, Xue
    Zhang, Jing
    Fu, Qin
    MOLECULAR MEDICINE REPORTS, 2016, 13 (01) : 769 - 777
  • [2] Expression of the receptor activator for nuclear factor-κB ligand and osteoprotegerin in chronic otitis media
    Kuczkowski, Jerzy
    Sakowicz-Burkiewicz, Monika
    Izycka-Swieszewska, Ewa
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2010, 31 (06) : 404 - 409
  • [3] Platelet-rich fibrin increases the osteoprotegerin/receptor activator of nuclear factor-κB ligand ratio in osteoblasts
    Sumida, Ryuta
    Maeda, Toyonobu
    Kawahara, Ichiro
    Yusa, Junko
    Kato, Yasumasa
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (01) : 358 - 365
  • [4] Differential expression of receptor activator of nuclear factor-κB ligand and osteoprotegerin mRNA in periodontal diseases
    Bostanci, N.
    Ilgenli, T.
    Emingil, G.
    Afacan, B.
    Han, B.
    Toz, H.
    Berdeli, A.
    Atilla, G.
    McKay, I. J.
    Hughes, F. J.
    Belibasakis, G. N.
    JOURNAL OF PERIODONTAL RESEARCH, 2007, 42 (04) : 287 - 293
  • [5] Effects of 17β-estradiol on adiponectin regulation of the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand
    Wang, Qing-Ping
    Yang, Li
    Li, Xian-Ping
    Xie, Hui
    Liao, Er-Yuan
    Wang, Min
    Luo, Xiang-Hang
    BONE, 2012, 51 (03) : 515 - 523
  • [6] The Effect of Osteoprotegerin (OPG)/Receptor Activator of Nuclear Factor-κB Ligand (RANKL)/Receptor Activator of Nuclear Factor-κB (RANK) on Aortic Valve Calcified
    Luo, Wei
    Wang, Jing
    Yang, Xia
    Li, Junshan
    Song, Yanqiu
    Cong, Hongliang
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2024, 54 (05): : 633 - 642
  • [7] In vitro expression of receptor activator of nuclear factor-κB ligand and osteoprotegerin in cultured equine articular cells
    Byron, Christopher R.
    Barger, Anne M.
    Stewart, Allison A.
    Pondenis, Holly C.
    Fan, Timothy M.
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2010, 71 (06) : 615 - 622
  • [8] Does osteoprotegerin or receptor activator of nuclear factor-κB ligand mediate the association between bone and coronary artery calcification?
    Bakhireva, Ludmila N.
    Laughlin, Gail A.
    Bettencourt, Ricki
    Barrett-Connor, Elizabeth
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (05): : 2009 - 2012
  • [9] Osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) in the serum of healthy adults
    Jung, K
    Lein, M
    Von Hösslin, K
    Grosse, A
    Roth, S
    Possinger, K
    Lüftner, D
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2002, 17 (03): : 177 - 181
  • [10] Plasma levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in patients with neuroblastoma
    Granchi, D
    Garaventa, A
    Amato, I
    Paolucci, P
    Baldini, N
    INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (01) : 146 - 151